• Mila Shakya, Rachel Colin-Jones, Katherine Theiss-Nyland, Merryn Voysey, Dikshya Pant, Nicola Smith, Xinxue Liu, Susan Tonks, Olga Mazur, Yama G Farooq, Jenny Clarke, Jennifer Hill, Anup Adhikari, Sabina Dongol, Abhilasha Karkey, Binod Bajracharya, Sarah Kelly, Meeru Gurung, Stephen Baker, Kathleen M Neuzil, Shrijana Shrestha, Buddha Basnyat, Andrew J Pollard, and TyVAC Nepal Study Team.
• From the Oxford University Clinical Research Unit (M.S., S.D., A.K., B. Basnyat), Patan Academy of Health Sciences, Patan Hospital (D.P., M.G., S.S.), the Nepal Family Development Foundation (A.A.), and Wasa Pasa Polyclinics Private, Lalitpur (B. Bajracharya) - all in Kathmandu; the Oxford Vaccine Group, Department of Paediatrics, University of Oxford, and the National Institute for Health Research Oxford Biomedical Research Centre, Oxford (R.C.-J., K.T.-N., M.V., N.S., X.L., S.T., O.M., Y.G.F., J.C., J.H., S.K., A.J.P.), and the Department of Medicine, University of Cambridge, Cambridge (S.B.) - all in the United Kingdom; the Oxford University Clinical Research Unit, Ho Chi Minh City, Vietnam (S.B.); and the University of Maryland School of Medicine, Baltimore (K.M.N.).
• N. Engl. J. Med. 2019 Dec 5; 381 (23): 220922182209-2218.

BackgroundSalmonella Typhi is a major cause of fever in children in low- and middle-income countries. A typhoid conjugate vaccine (TCV) that was recently prequalified by the World Health Organization was shown to be efficacious in a human challenge model, but data from efficacy trials in areas where typhoid is endemic are lacking.MethodsIn this phase 3, randomized, controlled trial in Lalitpur, Nepal, in which both the participants and observers were unaware of the trial-group assignments, we randomly assigned children who were between 9 months and 16 years of age, in a 1:1 ratio, to receive either a TCV or a capsular group A meningococcal conjugate vaccine (MenA) as a control. The primary outcome was typhoid fever confirmed by blood culture. We present the prespecified analysis of the primary and main secondary outcomes (including an immunogenicity subgroup); the 2-year trial follow-up is ongoing.ResultsA total of 10,005 participants received the TCV and 10,014 received the MenA vaccine. Blood culture-confirmed typhoid fever occurred in 7 participants who received TCV (79 cases per 100,000 person-years) and in 38 who received MenA vaccine (428 cases per 100,000 person-years) (vaccine efficacy, 81.6%; 95% confidence interval, 58.8 to 91.8; P<0.001). A total of 132 serious adverse events (61 in the TCV group and 71 in the MenA vaccine group) occurred in the first 6 months, and 1 event (pyrexia) was identified as being vaccine-related; the participant remained unaware of the trial-group assignment. Similar rates of adverse events were noted in the two trial groups; fever developed in 5.0% of participants in the TCV group and 5.4% in the MenA vaccine group in the first week after vaccination. In the immunogenicity subgroup, seroconversion (a Vi IgG level that at least quadrupled 28 days after vaccination) was 99% in the TCV group (677 of 683 participants) and 2% in the MenA vaccine group (8 of 380 participants).ConclusionsA single dose of TCV was immunogenic and effective in reducing S. Typhi bacteremia in children 9 months to 16 years of age. (Funded by the Bill and Melinda Gates Foundation; Current Controlled Trials number, ISRCTN43385161.).Copyright © 2019 Massachusetts Medical Society.

30 keywords...

hide…